We are advising TARGAN on the transaction

Davis Polk is advising TARGAN Inc. on its sale to Merck Animal Health, a division of Merck & Co., Inc. Upon closing, TARGAN’s biodevice technology will become part of Merck Animal Health’s commercial poultry portfolio. The transaction is expected to be completed in the third quarter of 2026, subject to regulatory approvals and other customary closing conditions.

TARGAN is an innovative animal AgTech systems company focused on transforming animal protein production industries worldwide. Founded in 2015 and based in Raleigh, North Carolina, the company’s mission is to provide affordable, individualized technologies that will improve speed, accuracy and animal welfare.

Merck Animal Health is a global animal health business committed to the science of healthier animals. For more than 130 years, it has pioneered groundbreaking science. Today, the company is driven by continuous innovation to develop breakthrough medicines, vaccines and technology.

The Davis Polk corporate team includes partner Michael Gilson and associates Michael Allen Nakamura and Costa Theodore. Partner William A. Curran and associate Shea Jendrusina are providing tax advice. Partner Travis Triano and associate Janice Perri are providing executive compensation advice. Partner David R. Bauer and associate Francesca Masella are providing intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post